Trending News

ANE Achieves 64.2% Adjusted Net Profit Growth in 2024, Beating Both Revenue and Profit Guidance to Dominate the Market

SHANGHAI, March 21, 2025 /PRNewswire/ -- On March 20, ANE (Stock Code: 9956.HK), China's leading less-than-truckload (LTL) market leader, announced its 2024 annual results. Key highlights include:  - LTL freight volume: 14.15 million tons (+17.5% YoY)  - Revenue: RMB11.58 billion (+16.7% YoY)  - Gross profit: RMB1.84 billion (+45.2%...

Media Advisory: Transit Announcement in Squamish

SQUAMISH, BC, March 20, 2025 /CNW/ - Members of the media are invited to a transit announcement with Patrick Weiler, Member of Parliament for West Vancouver - Sunshine Coast - Sea to Sky Country, His Worship Armand Hurford, Mayor of the District of Squamish, and...

Akeso's Cadonilimab Combined with Concurrent Chemoradiotherapy Demonstrates Promising Efficacy in Locally Advanced Cervical Cancer: Data Published at the 2025 SGO Annual Meeting

HONG KONG, March 20, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) presented promising phase III safety run-in results from the COMPASSION-18/AK104-305 study, at the 2025 Annual Meeting of the Society of Gynecologic Oncology (SGO). The study evaluates the global first-in-class PD-1/CTLA-4 bispecific antibody, cadonilimab (AK104),...

Dive Deeper News Reviews

Bitcoin DeFi Could Help Bitcoin Big in 2025

Bitcoin is making a comeback, in more than just the price. People are looking for ways in which to best utilize their Bitcoin, and Bitcoin DeFi is the latest trend. While Bitcoin is always looking for ways to enter the markets, including traditional real estate, lending, to simply spending it like cash. Up until this cycle, answering the question of how do I use my Bitcoin...

Latest Reviews

More Reviews

More Industry News

U.S. FDA approves TREMFYA® (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to...

TREMFYA® is the only IL-23i to demonstrate clinical remission and endoscopic response, both at one year, with a fully subcutaneous induction regimen Supported by data from the GALAXI study, TREMFYA® is the only IL-23i to show superiority versus STELARA® in all pooled endoscopic endpoints within a double-blinded registrational trial  TREMFYA® approval in Crohn's disease builds upon recent ulcerative colitis FDA approval, marking the fourth indication for...

More Industry News

Videos

WeeklyReviewer - Industry News, Reviews and More! WeeklyReviewer industry news

Coronavirus Statistics

Latest Global Covid-19 Coronavirus Statistics By Country

The Covid-19 Coronavirus is a major pandemic spreading globally. This page is dedicated to providing up to date statistics on the Confirmed Cases, Confirmed Deaths, Recovered Patients, and Active Cases of Coronavirus around the world.

WeeklyReviewer News and News Reviews

WeeklyReviewer News, News Reviews and Analysis of Major News

WeeklyReviewer publishes industry news and reviews daily, engaging readers with press releases, news and reviews across major industries and sectors. Read our Dive Deeper News Reviews for more thorough analysis on major debates and conversations.

WeeklyReviewer - Industry News, Reviews and More! WeeklyReviewer industry news